Aktis Oncology Inc

NAS:AKTSHealthcareCBOEFTSE:MRUTNASDAQ:NQUSSG

$15.65+3.57%LiveIn session · ≈ AED 57.47 · Market cap $870.45M · Next earnings Thu 12 Nov

USD millions	FY2022	FY2023	FY2024	FY2025	YoY
Net income	(17.9)	(28.6)	(44.0)	(63.7)	−44.9%
Depreciation & amortization	0.4	1.1	1.6	2.3	+47.9%
Stock-based compensation	0.7	1.5	2.3	5.1	+127.0%
Change in working capital	(1.1)	(0.0)	59.0	(3.2)	−105.5%
Operating cash flow	(18.1)	(30.0)	14.8	(64.1)	−534.4%
Capital expenditure	(2.3)	(3.8)	(2.9)	(9.6)	−234.9%
Acquisitions	0.0	0.0	0.0	0.0	—
Investing cash flow	(2.3)	(68.8)	(190.4)	66.0	+134.6%
Dividends paid	0.0	0.0	0.0	0.0	—
Share buybacks	0.0	0.0	0.0	0.0	—
Debt issued / repaid	0.0	0.0	0.0	0.0	—
Financing cash flow	120.0	0.0	183.3	(1.2)	−100.7%
Free cash flow	(20.4)	(33.8)	11.9	(73.7)	−719.4%
Net change in cash	99.6	(98.8)	7.6	0.6	−91.8%

USD millionsUpdated Thu 13 Aug ·

ⓘ

Amounts are shown in the stated units; per-share amounts and shares are unscaled. Negative amounts are in brackets.